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Routine viral load (VL) testing among persons living with Human Immunodeficiency Virus
(PLHIV) enables earlier detection of sub-optimal antiretroviral therapy (ART) adherence and
for appropriate management of treatment failure. Since adoption of this policy by Zimbabwe
in 2016, the extent of implementation is unclear. Therefore we set out to determine among
PLHIV ever enrolled on ART from 2004–2017 and in ART care for�12 months at health
facilities providing ART in Zimbabwe: numbers (proportions) with VL testing uptake, VL sup-
pression and subsequently switched to 2nd-line ART following confirmed virologic failure.
Materials and methods
We used retrospective data from the electronic Patient Monitoring System (ePMS) in which
PLHIV on ART are registered at 525 public and 4 private health facilities.
Results
Among the 392,832 PLHIV in ART care for�12 months, 99,721 (25.4%) had an initial VL
test done and results available of whom 81,932 (82%) were virally suppressed. Among
those with a VL>1000 copies/mL; 6,689 (37.2%) had a follow-up VL test and 4,086 (61%)
had unsuppressed VLs of whom only 1,749 (42.8%) were switched to 2nd-line ART. Lower
age particularly adolescents (10–19 years) were more likely (ARR 1.34; 95%CI: 1.25–1.44)
to have virologic failure.
Conclusion
The study findings provide insights to implementation gaps including limitations in VL test-
ing; low identification of high- risk PLHIV in care and lack of prompt utilization of test results.
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The use of electronic patient-level data has demonstrated its usefulness in assessing the
performance of the national VL testing program. By end of 2017 implementation of VL test-
ing was sub-optimal, and virological failure was relatively common, particularly among ado-
lescents. Of concern is evidence of failure to act on VL test results that were received. A
quality improvement initiative has been planned in response to these findings and its effect
on patient management will be monitored.
Introduction
Over the last decade significant progress has been made in scaling up human immunodefi-
ciency virus (HIV) treatment programs in low to middle-income countries (LMICs), with over
21 million people globally receiving antiretroviral therapy (ART) by 2017 [1].
Viral load (VL) is a direct measure of HIV treatment response. Studies have shown that
when an ART regimen is fully effective (i.e. no drug resistance) and adherence is optimized,
most PLHIV become virally suppressed with undetectable VLs (<50–1000 copies/ mL) within
six months of ART initiation [2, 3].
The World Health Organization recommends VL testing for monitoring adherence to, and
effectiveness of, ART among persons with HIV (PLHIV) to enable earlier detection of poor
adherence and management of treatment failure. Viral suppression allows immune recovery
and renders HIV- infected individuals non-infectious [4]. Virologic monitoring is universal in
high-income countries; however, it is limited in some low-income countries.
By the end of 2017, Zimbabwe had a population of 13 million people and an estimated 1.3
million adults and children living with HIV of whom approximately 1.1 million patients were
receiving ART [5]. The Zimbabwe National ART programme guidelines recommend use of
VL testing to monitor HIV treatment response, with testing performed at 6 months, 12
months and then yearly following ART initiation [6]. In Zimbabwe, about 73% of the PLHIV
reported knowing their HIV status, and 86.6% of those who knew their status report being on
ART [7]. It is estimated that 15% of those on ART had a VL� 1,000 copies/ml and therefore
they had not achieved VL suppression. By December 2017, fewer than 30% of PLHIV in ART
care had received at least one VL test in the public sector (estimates based on VL tests per-
formed, compared with a national target of 70% by 2017) [8]. Due to resource constraints,
prior to 2016 sub-populations were prioritized and these included pregnant women, children
and PLHIV suspected of treatment failure based on immunological or clinical criteria and
among PLHIV who had disengaged from care. Nevertheless, anecdotal reports suggest vari-
ability across health facilities with missed opportunities for effective monitoring and manage-
ment of PLHIV [9, 10]. As per national ARV Guidelines; PLHIV who have an unsuppressed
VL (defined as>1,000 copies/mL) undergo enhanced adherence counselling (EAC), followed
by a repeat VL test after 3 months with a switch in ART regimen (to second or third line ther-
apy as appropriate) if the VL remains unsuppressed [6]. However, the extent to which these
guidelines were followed under routine program conditions was unclear.
Our specific study objectives were to determine among PLHIV initiated on ART in Zimba-
bwe between 01 August 2004 and 01 January 2017: i) the number (proportion) who received
VL testing, and were virally suppressed ii) among those with an initial unsuppressed VL, the
number (proportion) with a subsequent VL test following EAC sessions, iii) the number (pro-
portion) switched to 2nd line ART among those with confirmed virological failure iv) and their
associated demographic and clinical factors.
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Materials and methods
Study design
This was a retrospective cohort study design using routinely collected programme data.
Setting
Zimbabwe offers HIV treatment and care services free of charge in public health facilities and
selected not-for-profit private health facilities, and these are integrated with provision of general
health services. There are 1,620 public health facilities offering HIV treatment and care services in
Zimbabwe across 10 provinces (including Harare and Bulawayo metropolitan provinces). These
health facilities are stratified into a four-tiers consisting of rural/urban primary health care (PHC)
facilities at the lowest level, district hospitals and selected faith-based hospitals at the secondary
referral level, 8 provincial hospitals at the third referral level and 5 central hospitals at the fourth
referral level. Health services are provided by nurses at the PHCs with doctors only found from
secondary referral level and above were theatre and laboratory facilities are available.
Study sample
Our study focused on data from 529 health facilities (525 public and 4 private not-for-profit
health facilities) providing HIV treatment and care services and using the national Electronic
Patient Monitoring System (ePMS). The ePMS is an electronic-last system for capturing
patient-level demographic, clinical, and laboratory information at enrolment and for follow-
up review visits among PLHIV registered in HIV care. The system is in use at 529 high volume
health facilities (with�500 PLHIV on ART by December 2012) out of 1,620 health facilities
providing ART services in Zimbabwe. Despite the ePMS coming into use from 2012 onwards,
historical patient-visit data were entered for patients who were alive in ART care and had been
enrolled into care dating back to 2004 when ART was first offered in the public sector. To
ensure that analysis was restricted to those who were eligible for VL testing, we included in our
study only PLHIV enrolled into ART care between 01 August 2004 and 01 January 2017
(regardless of age) who were still alive in ART care for at least 12 months beyond 30 June 2017
at health facilities with the ePMS.
HIV diagnosis and treatment services in Zimbabwe
Most PLHIV are HIV diagnosed at health facilities through provider-initiated or voluntary
HIV testing. Alternatively, HIV testing is conducted in the community through outreach pro-
grammes and index testing. The HIV testing algorithm is based on the WHO 2015 HIV testing
algorithm where an initial test is done using an Alere Determine HIV-1/2 Ag/Ab Combo
rapid HIV test or Standard Q rapid HIV test followed by a confirmatory rapid HIV test using
a First Response HIV 1-2-0 Card test or Chembio if the initial test is HIV-positive. If these
tests are discordant they are repeated in parallel, with a final result concluded by concordant
results. If still discordant, a third test (INSTI) is performed. Once diagnosed positive for HIV,
a patient is retested for verification before enrolment into HIV care where they are prepared
and counselled for ART [6].
By end of 2018, the preferred first-line ART regimen among adolescents (10–19 years) and
adults (20+ years) was a once-daily fixed-dose combination of Tenofovir (TDF) 300mg plus
Lamivudine (3TC) 300mg plus Efavirenz (EFV) 400mg. The alternative first-line regimen was
a combination of TDF (300mg)+3TC (300mg) and Nevirapine (NVP) 200mg. However, use of
Nevirapine for HIV treatment has since been phased out. Zidovudine could be used as a sub-
stitute for Tenofovir. For those with confirmed virologic failure, the preferred second-line
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ART regimen consisted of Zidovudine (AZT) + 3TC + Atazanavir (ATV/r) or Lopinavir
(LPV/r) if TDF was used in the first-line regimen. Alternatively, TDF could be used if AZT
was used in the first-line ART regimen. Those failing second-line ART were referred for spe-
cialist assessment which included a viral load test and genotype testing prior to commencing
third line ART. Medicines used as 3rd line ART consist of Dolutegravir (DTG) 50mg and Dar-
unavir (600mg)/Ritonavir (100mg) twice daily. Raltegravir (400mg) twice daily could be used
when DTG was not available [6].
Viral load testing services in Zimbabwe
In Zimbabwe, VL testing is offered free of charge at public health facilities and has been decen-
tralized to six provinces with 18 high through-put platforms situated in laboratories at selected
third- and fourth- level referral health facilities. VL samples are collected from health facilities
using either Dried Blood Spot (DBS) samples for testing using Biomérieux NucliSENS and
Abbott m2000 platforms or whole blood samples for testing using the Roche Taqman as well
as the Abbott m2000 platforms. These samples are then transported to collection points (hubs)
prior to being couriered to the laboratory. There are also 25 second-level health facilities with
SAMBA Semi-Q point-of-care VL machines although they have very low testing capacity. Fig
1 shows health facilities with the ePMS versus those with VL machines onsite.
CD4 testing still remains important for assessing patients with CD4<100 cells/mL requir-
ing routine screening for crypotococcal meningitis using an antigen test and TB screening
using the urine lipoaribomannan assay test. The CD4 test was also important for determining
Fig 1. Distribution of health facilities using the ePMS versus those with highthroughput viral load testing machines and point-of-
care testing machines. ePMS = electronic Patient Monitoring System; POC VL = point-of-care viral load.
https://doi.org/10.1371/journal.pone.0245720.g001
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ART eligibility among those with CD4 cells counts below the 200-, 350- and eventually 500-
thresholds overtime, prior to adoption of the “HIV treat-all” approach in mid-2016 where all
HIV-diagnosed PLHIV were eligible for ART initiation, regardless of CD4 count.
Data management
The primary source document for data variables included in this study was the individual ART
care booklet which is entered in the ePMS. Data variables abstracted from the EPMS for pur-
poses of this study include sex, date of birth, date of ART initiation, WHO clinical staging,
CD4 cell count, current pregnancy status, anemia status at enrolment, dates of VL sample col-
lection and VL test results and date of switching to 2nd-line ART. Current pregnancy status
referred to the last visit when data was collected from 30 June 2017 onwards among the
women living with HIV (WLHIV) who were included in this study. This definition was chosen
since women are eligible for VL testing during pregnancy in order to assess whether they are
at high risk or low risk of mother-to-child transmission of HIV. Anemia was defined as having
hemoglobin levels <13.5g/dL among men or <12g/dL among women.
The ePMS is an offline system with a MySQL database format (Oracle International Corpora-
tion, Redwood City, CA, USA) with a Microsoft Access front-end. Upon receipt of routine quar-
terly submissions of health facility-level data back-up files for the October-December 4 2018
period, selected variables were imported using Stata version 15 (StataCorp, College Station, Texas
USA) through the “OBDC data source” command into separate datasets for demographics, clini-
cal data, laboratory tests and patient follow-up visit data. These were separate datasets which were
merged into health facility-specific datasets and then appended into one large dataset.
The ART number (which is a unique identifier assigned to a patient upon enrolment into
life-long HIV care) was used to de-duplicate data for patients who transferred from one health
facility to another with the ePMS installed and also to account for their current ART outcomes,
especially for patients who were self-transfers and might have been misclassified as lost-to-fol-
low up. However, this was not possible for a patient who might have self-transferred to another
health facility and presented as a new patient and therefore assigned a new ART number. We
also could not determine the true ART outcomes among self-transfers who might have relo-
cated to other health facilities without the ePMS, given that this is available in approximately
40% (634/1,560) of all health facilities.
Statistical analysis
Categorical variables were summarized by frequencies and proportions whilst continuous
skewed variables were summarized as medians and interquartile ranges.
The outcomes of interest were the proportion of those on ART who i) had ever had a VL
test ii) had an initial unsuppressed VL iii) had a repeat VL test (among those with an initial
unsuppressed VL), iv) had confirmed virologic failure and v) had switched to 2nd-line ART fol-
lowing confirmed virologic failure. An unsuppressed viral load is any VL measurement that is
�1,000 copies/ml whilst a confirmed virologic failure is defined as a VL�1,000 copies/ml
based on two consecutive VL measurements within a 3-month interval following enhanced
adherence counselling and after being on ART for at least 6 months according to WHO [3].
However in this study, a confirmed virologic failure was defined as a documented follow-
up unsuppressed VL received within 9 months after date of the initial VL result and after being
on ART for at least 6 months. This was assuming that 3 months after the initial unsuppressed
VL there would be EAC sessions whilst the 3 to 6 months after EAC was to account for date of
receipt of the VL result. The censoring date for this study was therefore set at 31 December
2018 to account for those initiated on ART by 01 January 2017.
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Bivariate analyses using the Chi square test were done to determine associations between
various demographic and clinical characteristics and ever having a VL test done and to com-
pare proportions with VL suppression by gender between the different age groups. We also
calculated unadjusted and multivariable-adjusted relative risks and their 95% confidence inter-
vals in order to determine factors associated with having a follow-up unsuppressed VL using a
generalized linear model with a log link and poisson distribution with a robust error variance.
All variables with a p value<0.25 in the Chi Square test for associations with having an unsup-
pressed follow-up VL result were included in the multivariate adjusted regression model. Vari-
ables adjusted for were province, sex, age group, current pregnancy status, WHO clinical
staging, baseline CD4 cell count, ART regimen prior to a first VL test, time to the first VL test
since ART initiation and level of health care facility. All p-values less than 0.05 were statistically
significant.
Ethics approval
This study was approved by the Medical Research Council of Zimbabwe (Approval Number:
MRCZ/A/2160) and the Joint Research Ethics Committee (JREC) for University of Zimbabwe
College of Health Sciences and Parirenyatwa Group Hospitals (Approval Number: JREC/12/
17). The ethics committee waived the requirement for informed consent by participants as VL
testing is part of ministry of health routine standard of care for monitoring HIV treatment
response. Data were also fully anonymized as patient names were excluded in the abstraction
of data. Instead patient ART numbers (which are unique identifiers assigned to patients upon
enrolment in HIV care) were abstracted and later replaced in the electronic database with a
sequential number to ensure patients cannot be traced back to the facility.
Results
Overall, there were 392,832 study participants included in our study who had been initiated on
ART and entered in the ePMS across 529 health facilities in Zimbabwe and had been on ART
for at least 12 months. Fig 2 shows the cumulative number of PLHIV initiated on ART by year
versus the proportion with at least one VL test done, care for at least 12 months and entered in
the ePMS. There was an exponential increase in VL coverage from<1% in 2004 when the pub-
lic sector ART programme started to 25.4% by 2018 as the cumulative number increased from
2,723 to 392,832 over the same periods.
Table 1 shows variations in the proportions of active patients on ART who had ever had a
VL test by province, ranging from 43% in Manicaland to only 10% in Mashonaland Central.
There were no gender differences observed (males: 24.9%; females: 25.7%). Higher proportions
of adolescents (10–19 years) and patients aged above 50 years (29.05% and 29.28% respec-
tively) had had a VL test compared with other age groups. Women who were not pregnant
were more likely to have accessed at least one VL test compared to pregnant women (26.2% vs
17.5%). Those initiated on ART within the primary care level (22%) were less likely to have
had a VL test than those at higher level facilities. Patients who had presented at ART enroll-
ment with advanced HIV disease or with low CD4 of<200 cells per ml were more likely to
have had at least one VL test done. Patients receiving 2nd line ART were twice as likely to have
had a VL test done (47.8%) compared to those on 1st line ART (24.6%).
The proportion of PLHIV with viral suppression improved from 72.9% (95% confidence
interval (CI): 70.4–75.2) in 2013 to 83.5% (95% CI: 83.2–83.8) in 2017(Fig 3).
Fig 4 shows comparisons in proportions of PLHIV in ART care with suppressed VLs for
the first VL test when stratified by age group and sex. Adolescents aged 10–19 years were least
likely to be suppressed compared to other age groups. There were also significantly higher
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proportions with viral suppression among females compared to males for all pairwise compari-
sons by age group i.e. (p<0.001)
Fig 5 shows a flow chart portraying uptake of an initial VL, proportion with unsuppressed
VLs, subsequent access to follow-up VL test, confirmed virologic failure and proportions
switched to second-line ARVs among PLHIV in ART care for at least 12 months and active in
care beyond 31 March 2017. Of 392,832 PLHIV, 99,902 (25.4%) had ever had a VL test done.
Median time to first VL test from start of ART was 63 months (IQR, 37–88) based on available
data for 99,721 (99.8%) patients. Among the 99,721 active patients for whom VL data was
available; 82% (81,932/99,721) were virally suppressed based on the initial VL test while the
remainder 18% (17,970/99,721) had a VL of>1,000 copies/ml. Of the 17,970 with unsup-
pressed 1st VLs, 37.2% (6,689/17,970) had a follow-up VL test. Data on dates for both 1st and
2nd VL tests was available for 6,314 /6,689 (94.4%) patients with 1st VL test that was unsup-
pressed. Of these 6,314 patients, the time from the 1st unsuppressed VL test to the 2nd VL test
was a median of 187 days, (IQR, 120–302).
Following an initial unsuppressed VL test result, among those who had a follow up VL test
(n = 6689), 38.9% had a suppressed VL test at follow up. Fewer than half of the patients with a
2nd unsuppressed VL test were switched to 2nd line ART (42.8%; 1,749/4,086), of whom—
1,528/1,749 (87.4%) switched from 1st- to 2nd-line ART whilst 157/1749 (9%) previously on
2nd-line ART and 64/1,749 (3.7%) had their ART regimen prior to the initial ART regimen
Fig 2. Trend in VL testing coverage and number of PLHIV enrolled in ART care between 2004 and 2017 in health facilities using ePMS with at least 12 months in
ART care. PLHIV = people living with HIV; ART = antiretroviral therapy; VL = viral load; ePMS = electronic Patient Monitoring System. NB: The numbers of patients
enrolled in ART care are similar for 2016,2017 and 2018 as they refer only to those patients initiated on ART between 01 August 2004–01 January 2017 who were in ART
care for at least 12 months and alive beyond 30 June 2017. The VL coverage extends to 2018 to account for patient started on ART from October-December 2016 onwards
and eligible for a VL test after being in ART care for at least 12 months and also allowed for a window period for delayed access to a VL test.
https://doi.org/10.1371/journal.pone.0245720.g002
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Table 1. Coverage of ever receiving viral load testing by demographic and clinical characteristics of PLHIV
enrolled in the ART programme for>12 months in health facilities using the electronic Patient Management Sys-
tem between 2004 and 2017 in Zimbabwe.
Characteristic Ever had a viral load test done?
Yes No P-value�(N = 392,832)
N (%) N (%)
Total 99902 (25.43) 292930 (74.57)
Province (n = 392,831)
Harare 2467 (20.84) 9370 (79.16) <0.001
Manicaland 19150 (42.63) 25776 (57.37)
Mash Central 3332 (10.3) 29022 (89.7)
Mash East 15982 (24.23) 49988 (75.77)
Mash West 6949 (18.99) 29651 (81.01)
Mat North 6332 (18.46) 27976 (81.54)
Mat South 3698 (11.68) 27975 (88.32)
Midlands 13364 (25.47) 39110 (74.53)
Masvingo 16936 (36.44) 29537 (63.56)
Bulawayo 11692 (32.28) 24524 (67.72)
Sex (n = 392,831)
Female 64431 (25.71) 186200 (74.29) <0.001
Male 35471 (24.94) 106729 (75.06)
Age group at last visit
(n = 392,822)
<10 yrs 2551 (23.16) 8462 (76.84) <0.001
10–19 yrs 6453 (29.05) 15757 (70.95)
20–29 yrs 8018 (19.48) 33150 (80.52)
30–39 yrs 25723 (22.58) 88210 (77.42)
40–49 yrs 32637 (27.03) 88121 (72.97)
50+ yrs 24520 (29.28) 59220 (70.72)
Current pregnancy status at last visit (n = 250,630)
No 61840 (26.2) 173989 (73.8) <0.001
Yes 2590 (17.5) 12211 (82.5)
Level of care at ART initiation (n = 392,831)
Primary health care 44682 (22.48) 154083 (77.52) <0.001
First Referral Level 46041 (27.64) 120532 (72.36)
Second Referral Level 5469 (36.35) 9575 (63.65)
Third Referral Level 3710 (29.8) 8739 (70.2)
Baseline WHO Stage (n = 172,904)
I 7662 (22.82) 25917 (77.18) <0.001
II 12932 (23.21) 42776 (76.79)
III 19018 (23.72) 61162 (76.28)
IV 1115 (32.44) 2322 (67.56)
Baseline CD4 count (cells/mL) (n = 115,158)
= /<200 15948 (30.4) 36511 (69.6) <0.001
201–350 10223 (27.79) 26570 (72.21)
351–500 3624 (23.57) 11751 (76.43)
501/2000 2353 (22.34) 8178 (77.66)
Currently on TB treatment at last visit (n = 392,382)
Yes 1149 (27.9) 2973 (72.1) <0.001
No 98753 (25.4) 289957 (74.6)
(Continued)
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unspecified. Of the 749 with complete data, time to switch to 2nd line ART after the 2nd VL test
was a median of 89 days (IQR, 40–182).
A total of 17,970 active patients had an unsuppressed initial VL result (Fig 5 and Table 2).
Provinces with the highest proportions of patients with unsuppressed VL were Harare
Table 1. (Continued)
Characteristic Ever had a viral load test done?
Yes No P-value�(N = 392,832)
N (%) N (%)
Anemia at baseline
(n = 392,382)
Yes 744 (28.76) 1843 (71.24) 0.165
No 99158 (30.34) 291087 (69.66)
Current ART regimen at last visit (n = 391,300)
1st-line 92723 (24.64) 283587 (75.36) 0.222
2nd-line 7168 (47.82) 7822 (52.18)
�The p-values shown are for the chi square test for associations between having a VL test ever done and the various
demographic and clinical characteristics excluding unrecorded data for each variable.
https://doi.org/10.1371/journal.pone.0245720.t001
Fig 3. Number of PLHIV with at least one VL test done and proportions with viral suppression by year among those initiated ART between 2013–2017 and in
care for at least 12 months at health facilities using ePMS and alive beyond 30 June 2017. VL = viral suppression; ART = antiretroviral therapy; ePMS = electronic
Patient Monitoring System. NB: 652 patients with VL tests done between 2004 and 2012 out of the 99,902 with VL tests done between 2004 and 2018 have been excluded
given the small numbers and the high probability of survival bias given that the ePMS was rolled out in January 2013 hence those who were alive among those initiated on
ART before 2013 were likely entered in the system resulting in biased proportions with viral suppression.
https://doi.org/10.1371/journal.pone.0245720.g003
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(21.1%), Mashonaland Central (21.2%) and Bulawayo (23%). Males compared to females had a
higher proportion of patients with unsuppressed VL (21% vs 16.4%).
Table 3 below shows that the prevalance of virologic failure varies by province and age with
younger age groups particularly the adolescents (ARR 1.34; 95%CI: 1.25–1.44) and pediatrics
(ARR 1.34; 95% CI: 1.22–1.46) being more likely to have virologic failure. Patients on second
line ART were 30% less likely to have virologic failure on a repeat VL test compared to those
receiving first line ART (ARR 0.70; 95% CI: 0.62–0.78). Time taken to initial VL test was an
important predictor of virologic failure in repeat testing. Patients who had been on ART for
>5 years before having their first VL test were 46% more likely to have virologic failure (ARR
1.46; 95% CI: 1.24–1.71) compared to those who had the initial VL�6 months post ART
initiation.
Discussion
This is the first study to assess provision of public sector VL testing services in Zimbabwe
using the ePMS system, demonstrating its ability to track patients in general and VL testing
scale up overtime. The study results revealed that only a quarter (25.4%) of the active ART
patients had ever had a VL test done, and among those with a first high VL, 37.2% had a repeat
VL test done. As shown in population based and clinical studies; high-risk populations
included adolescents and males who were least likely to have an initial suppressed VL [11, 12].
Proportions of PLHIV with VL suppression were high and had improved from 72.9% in 2013
Fig 4. Comparison in proportions of PLHIV with VL suppression for the first VL test stratified by age-group and sex by year among those in ART care for at least
12 months between 2013 and 2017 at health facilities using ePMS.
https://doi.org/10.1371/journal.pone.0245720.g004
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to over 83.5% in 2018 similar to what has been reported elsewhere [7]. However, the propor-
tions with VL suppression were lower than what has been reported in other African countries
such as Botswana (95.6%), Malawi (90.8%) and Rwanda (93.2%) [12].
This study used secondary analysis of data collected via Zimbabwe’s ePMS deployed at
most high-volume health facilities providing ART services in Zimbabwe, across all the four
tiers of the health care delivery system and includes 840,971 PLHIV. Of note 75% of all ART
patients in Zimbabwe are captured within ePMS (the system excludes low volume health facili-
ties including some private sector health facilities).
Importantly only a quarter of the active ART patients had accessed an initial VL test by end
2017 which is in contrast to higher VL testing coverage of over 75% of individuals on ART
each year reported in recent years in some African countries including South Africa, Namibia,
Kenya, and Uganda [13]. Other countries such as Tanzania reported low VL coverage at 9%
[14]. This calls for urgent attention to treatment monitoring and especially among patients
decentralized to primary care facilities who had less access to a VL test. A systematic review
conducted by Pham et al (2017) revealed low coverage of monitoring tests in rural areas [15].
Improved coverage of VL testing would enable clinicians to determine which patients are sta-
ble on treatment, and eligible for reduced annual clinical reviews as outlined in Zimbabwe’s
differentiated care policy for stable patients [16, 17].
Possible reasons for the low VL coverage include limited VL testing capacity; inadequate
and centralized VL platforms with limited Point of Care VL devices, limited transportation
systems of specimens from peripheral health facilities to central laboratories, stock-outs of
reagents; and few laboratory scientists to perform the tests. A survey conducted by WHO in
Fig 5. Flow chart showing the management of PLHIV still in ART care beyond 30 June 2017 and with unsuppressed viral load result in 2017 in the Zimbabwe
ART program at health facilities using the electronic Patient Management System.
https://doi.org/10.1371/journal.pone.0245720.g005
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Table 2. Demographic and clinical characteristics of PLHIV on ART for�12 months with an initial unsuppressed
viral load (>1000 copies/mL) at sites using the electronic Patient Management System from 2004 to 2017 in
Zimbabwe.




Total 99,902 17,970 (17.99)
Province (n = 17,970)
Harare 2,467 520 (21.1)
Manicaland 19,150 3,692 (19.3)
Mash Central 3,332 707 (21.2)
Mash East 15,982 2,508 (15.7)
Mash West 6,949 1,167 (16.8)
Mat North 6,332 1,089 (17.2)
Mat South 3,698 720 (19.5)
Midlands 13,364 2,143 (16.0)
Masvingo 16,936 2,732 (16.1)
Bulawayo 11,692 2,692 (23.0)
Sex (n = 17,970)
Female 64,431 10,539 (16.4)
Male 35,471 7,431 (21.0)
Age group (n = 17,970)
<10 yrs 2,551 1,009 (39.6)
10–19 yrs 6,453 2,686 (41.6)
20–29 yrs 8,018 1,895 (23.6)
30–39 yrs 25,723 4,542 (17.7)
40–49 yrs 32,637 4,901 (15.0)





WHO staging (n = 7,315)
I 7,662 1,187 (15.5)
II 12,932 2,286 (17.7)
III 19,018 3,605 (19.0)
IV 1,115 237 (21.3)
On TB treatment at enrolment (n = 17,970)
No 98,753 17792 (18.0)
Yes 1,149 178 (15.5)
Baseline CD4 count (cells/mL) (n = 4,969)
= /<200 15,948 2,926 (18.4)
201–350 10,223 1,309 (12.8)
351–500 3,624 445 (12.3)
501/2000 2,353 289 (12.3)
ART regimen prior to 1st VL test (n = 17,182)
1st-line 94,550 16,302 (17.2)
2nd-line 3,609 880 (24.4)
Time to 1st VL test from ART initiation (n = 17,916)
(Continued)
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low to middle-income countries (LMICs) in 2014 cited several reasons for slow implementa-
tion of VL testing including financial constraints, insufficient and overburdened healthcare
professionals, poor training and lack of knowledge, and weak transport and laboratory systems
[18]. The national ART program is reviewing its implementation bottlenecks for the VL strat-
egy with a view to fast track its national rollout. The recent introduction of Point of Care VL
technologies in Zimbabwe for remote areas presents an opportunity to address equity con-
cerns for VL access. Patient education on the benefits of VL testing would likely create demand
for the service.
The median time from ART enrolment to 1st VL test was over 5 years, because scale up of
routine VL testing only started in 2016. We would anticipate that time to first VL will reduce
as roll out continues. Health care worker training will be critical to ensure timely testing and
that results are acted on appropriately.
As shown, management of patients with an unsuppressed initial VL test was sub-optimal.
Around a third (37%) had a repeat VL test done within 9 month of the first test, despite guide-
lines for 100% retesting by 3 months. Wide variations in the uptake of a repeat VL test follow-
ing an unsuppressed VL exists in literature. A study in Mozambique during 2014–2015 at MSF
facilities showed comparable low proportions of patients with follow-up VL tests done among
those with a high first VL result (35%) [19] with 88.5% reported from a rural district in
Rwanda [12]. National ART Guidelines state that patients with an initial unsuppressed VL
results should undergo 3 EAC sessions followed by a repeat VL test after 3 months to confirm
viral failure. Possible reasons for low uptake of the repeat VL test may be limited awareness of
the VL testing algorithm and poor documentation of the VL test result.
Of concern were delays in switching patients to 2nd line ART after the 2nd VL test (median
of 89 days; IQR, 40–182) which contrasts other studies in rural Rwanda (median of 17 days
IQR: 8–42)) [12]. Lengthy delays in switching patients to second line ART have also been
reported in KwaZulu, Natal, South Africa (median time of 6.4 months; IQR 0–43.3 months)
and in Uganda (8.1 months; IQR: 3.7–17) [20, 21]. The VL sample transport system and feed-
back of the results has been inefficient and fragmented with multiple courier systems, lack of
Table 2. (Continued)




�6 months 1,610 493 (30.6)
7–12 months 4,319 743 (17.2)
1-2yrs 8,646 1,440 (16.7)
3-5yrs 32,754 5,968 (18.2)
>5yrs 52,392 9,272 (17.7)
Level of Care (n = 17,970)
Primary health care 44,682 7400 (16.6)
First Referral Level 46,041 8412 (18.3)
Second Referral Level 5,469 1109 (20.3)
Third Referral Level 3,710 1049 (28.3)
PLHIV = People Living with HIV; ART = antiretroviral therapy; WHO = World Health Organization;
TB = tuberculosis; VL = viral load.
: Patients have been in active in care for�12 months beyond 30 June 2017.
https://doi.org/10.1371/journal.pone.0245720.t002
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Table 3. Generalized linear regression model of demographic & clinical characteristics associated with confirmed virologic failure on repeat testing among PLHIV
in ART care for�12 months at health facilities using the electronic Patient Management System from 2004 to 2017 in Zimbabwe.
Characteristic Total Repeat VL>1000 copies/ml RR (95% CI) ARR (95% CI)
N n (%)
Total 6689 4086 (61.1)
Province
Harare 313 151 (47.9) Reference Reference
Manicaland 1934 1254 (64.9) 1.35 (1.20–1.53) 1.61 (1.37–1.89)
Mash Central 107 81 (75.0) 1.56 (1.34–1.83) 1.83 (1.52–2.21)
Mash East 798 468 (58.7) 1.22 (1.08–1.39) 1.51 (1.28–1.79)
Mash West 371 194 (52.2) 1.09 (0.94–1.26) 1.38 (1.15–1.66)
Mat North 266 138 (51.9) 1.08 (0.92–1.27) 1.28 (1.05–1.55)
Mat South 108 79 (73.2) 1.53 (1.30–1.79) 1.82 (1.49–2.22)
Midlands 637 489 (76.9) 1.60 (1.42–1.81) 1.85 (1.57–2.18)
Masvingo 976 567 (58.1) 1.21 (1.07–1.38) 1.47 (1.25–1.74)
Bulawayo 1179 665 (56.5) 1.18 (1.04–1.34) 1.35 (1.17–1.56)
Sex
Female 3,919 2369 (60.5) Reference Reference
Male 2,770 1717 (62.0) 1.03 (0.99–1.07) 1.03 (0.99–1.07)
Age group
50+ yrs 1,173 616 (52.5) Reference Reference
40–49 yrs 1,789 1055 (56.0) 1.12 (1.05–1.20) 1.12 (1.05–1.20)
30–39 yrs 1,500 922 (61.5) 1.17 (1.09–1.25) 1.19 (1.11–1.28)
20–29 yrs 629 409 (65.0) 1.24 (1.14–1.34) 1.27 (1.18–1.38)
10–19 yrs 1,186 811 (68.4) 1.30 (1.22–1.39) 1.34 (1.25–1.44)
<10 yrs 412 273 (66.3) 1.26 (1.16–1.38) 1.34 (1.22–1.46)
Current pregnancy status
No 3,792 1495 (39.4) Reference Reference
Yes 127 55 (43.3) 0.94 (0.80–1.09) 1.01 (0.82–1.25)
WHO Stage
I 381 158 (41.5) Reference Reference
II 820 304 (37.1) 1.08 (0.98–1.20) 1.04 (0.95–1.15)
III 1,338 526 (39.3) 1.04 (0.94–1.14) 1.01 (0.92–1.11)
IV 101 41 (40.6) 1.02 (0.85–1.22) 0.98 (0.83–1.17)
Not recorded 4,049 1574 (38.9) 1.05 (0.96–1.15) 1.05 (0.96–1.15)
On TB treatment at enrolment
No 6,614 2297 (60.6) Reference Reference
Yes 75 72 (56.7) 1.03 (0.86–1.22) -
Baseline CD4 count (cells/mL)
= /<200 1,075 677 (63.0) Reference Reference
201–350 446 243 (54.5) 0.87 (0.79–0.95) 0.85 (0.78–0.94)
351–500 123 63 (51.2) 0.81 (0.68–0.97) 0.83 (0.70–0.98)
>500 80 34 (42.5) 0.67 (0.52–0.87) 0.70 (0.54–0.89)
Not recorded 4,965 3069 (61.8) 0.98 (0.93–1.03) 0.94 (0.89–0.99)
ART regimen prior to 1st VL test
1st-line 6,055 3805 (62.8) Reference Reference
2nd-line 356 160 (44.9) 0.72 (0.64–0.8) 0.70 (0.62–0.78)
Not recorded 278 121 (43.5) 0.69 (0.6–0.79) 0.76 (0.66–0.88)
Time to 1st VL since ART initiation
(Continued)
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monitoring tools and, as a result, limited accountability between the couriers at peripheral and
FEDEX at the collection sites. This has resulted in long turn- around times from VL sample
collection to feedback of the VL results. Frequent downtimes laboratory equipment have also
contributed to the long VL result turn-around times, all these contributing to delays in switch-
ing patients with unsuppressed VLs to 2nd line ART.
Fewer than half of active patients (42.8%) with a 2nd unsuppressed VL test were switched to
a 2nd line ART regimen, suggesting that dissemination and training of clinicians in the revised
ARV Guidelines and the management of treatment failure has not been effective. A systematic
review from 16 sub-Saharan countries showed that 58% of patients with confirmed virologic
failure were switched to second line ART [22]. Clearly timely identification and management
of treatment failure cases to avert emergence of opportunistic infections and mortality from
high- risk patients are crucial to the ART program.
The levels of viral suppression among patients enrolled into the national ART program falls
below the UNAIDS 90-90-90 fast track targets. No gender differences were observed in access-
ing VL testing although in other studies [23] more women than men accessed the test. Despite
equal access to VL testing; males tended to experience viral failure more commonly than
females and similar findings were observed in the Zimbabwe Population-based HIV Impact
Assessment (ZIMPHIA) [7]. A previous study in Zimbabwe showed that males had higher
patient attrition and mortality compared to females due partly to late presentation for HIV
treatment and care [24]. A case-control study conducted in Burkina Faso by Penot P. et al in
2012, showed a strong association between male gender and virologic failure [25].
In 2019 Zimbabwe introduced dolutegravir, a potent integrase inhibitor as part of its first
line therapy. It has a higher barrier to resistance than efavirenz and fewer side effects. It is
hoped that this change in regimen will support a higher proportion of patients achieving viral
suppression.
Children and adolescent groups were the least likely to be virally suppressed (VL<1,000
copies/ml), consistent with the ZIMPHIA survey findings and studies conducted in Uganda,
Swaziland, Kenya and Mozambique [7, 23, 26, 27]. Poor adherence to ARV drugs is common
in children and adolescents. In children this is due to inadequate medication formulations, dif-
ficulties in administering medicines, drug toxicities and side effects, social context (example
Table 3. (Continued)
Characteristic Total Repeat VL>1000 copies/ml RR (95% CI) ARR (95% CI)
N n (%)
�6 months 238 97 (40.8) Reference Reference
7–12 months 280 141 (50.4) 1.24 (1.02–1.5) 1.16 (0.96–1.41)
1-2yrs 510 296 (58.0) 1.42 (1.2–1.69) 1.32 (1.12–1.57)
3-5yrs 2,269 1373 (60.5) 1.48 (1.27–1.74) 1.37 (1.17–1.61)
>5yrs 3,369 2165 (64.3) 1.58 (1.35–1.84) 1.46 (1.24–1.71)
Not recorded 23 14 (60.9) 1.49 (1.04–2.14) 1.59 (1.10–2.29)
Level of Care
Primary health care 2,221 1411 (63.5) Reference Reference
First Referral Level 3,274 1930 (59.0) 0.93 (0.89–0.97) 0.90 (0.86–0.94)
Second Referral Level 521 379 (72.7) 1.15 (1.08–1.22) 1.00 (0.94–1.06)
Third Referral Level 673 366 (54.4) 0.86 (0.79–0.92) 1.03 (0.93–1.15)
VL = viral load (copies/mL); HIV = Human Immunodeficiency Virus; ART = antiretroviral therapy; IQR = inter-quartile range; WHO = World Health Organisation;
TB = Tuberculosis; ART = antiretroviral therapy; RR = relative risk; ARR = multivariate-adjusted relative risk; CI = confidence interval.
https://doi.org/10.1371/journal.pone.0245720.t003
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lack of consistent caregiver). Adolescents frequently find long-term medication adherence dif-
ficult including HIV treatment [28] while some of them are not fully disclosed to of their HIV
status impacting negatively on their perceptions of, and importance of life-long HIV treat-
ment. The national program should prioritize interventions targeted at children and adoles-
cents including implementing differentiated service delivery models for adolescents such as
provision of adolescent-friendly services, peer- to- peer psychosocial support and counselling
services as well as encouraging adolescents to use reminders to take their pills. Health workers
should work closely with caregivers of infected children to provide adherence assessment, sup-
port, and education.
Lastly, factors associated with virologic failure included patients receiving 1st line ART and
patients with longer duration on ART. A recent study [29] conducted in Harare City provided
a similar findings where those on 2nd line ART (when compared to being on 1st line ART)
were more likely to have viral suppression, among patients with an initial unsuppressed VL.
The initial unsuppressed VL could be due to poor initial adherence, which was later corrected
by enrolment into EAC and the use of superior 2nd line Protease Inhibitor medicines. We also
found in our study that children and adolescents were more likely to have virologic failure and
this has been observed elsewhere, including people with low recent CD4 below 350 [27]. This
is likely due to psychosocial issues faced by these age groups (particularly the adolescents)
whereby they remain non-adherent to life-long therapy despite underoing EAC sessions.
This study has several strengths including: use of a huge data set with 75% of all ART
patients in Zimbabwe assessed over 13 years of follow up; the assessment of recent (2017) VL
scale up implementation and providing opportunities for quality improvement projects.
Study limitations included the exclusion of health facilities that had not started using the
ePMS. These are typically primary care facilities with low client volumes in rural settings.
Another limitation was that we exclusively used and analyzed programme data and so were
restricted to analysis of pre-determined data variables with some incomplete and inaccurate
data entries. Critically we were unable to assess whether patients received EAC sessions follow-
ing an initial unsuppressed VL test result or the socio-economic and educational status of
patients. We were also unable to ascertain whether a VL test was conducted based on clinical
need (ie ‘targeted’ testing) or as part of ‘routine’ scale up. Finally, we might have under-esti-
mated the uptake of VL testing services where documentation of medical records is poor, as
our study relied on a documented VL test result.
In conclusion, proportions of PLHIV with VL suppression improved from 72.9% in 2013 to
over 83.5% in 2018. The government’s policy of using VL testing as a routine practice for mon-
itoring adherence and treatment response provided opportunities to improve patient monitor-
ing and treatment outcomes however, due to its implementation gaps, treatment was not fully
optimized. Strengthening the capacity for VL testing, the identification of high- risk patients
with viral failure and prompt utilization of the test results is paramount for treatment optimi-
zation. A quality improvement (QI) intervention has been planned in Zimbabwe to respond to
these suboptimal results. The ePMS has demonstrated its usefulness in assessing the perfor-
mance of the national VL testing program albeit some limitations, in order to help policy-
makers to address identified bottlenecks that impede progress.
Author Contributions
Conceptualization: Tsitsi Apollo, Andrew Phillips, Chiratidzo Ndhlovu, Frances M. Cowan.
Data curation: Kudakwashe C. Takarinda.
Formal analysis: Kudakwashe C. Takarinda.
PLOS ONE Viral load uptake in ART care in Zimbabwe
PLOS ONE | https://doi.org/10.1371/journal.pone.0245720 January 22, 2021 16 / 18
Methodology: Tsitsi Apollo, Andrew Phillips, Chiratidzo Ndhlovu, Frances M. Cowan.
Supervision: Andrew Phillips, Chiratidzo Ndhlovu, Frances M. Cowan.
Validation: Kudakwashe C. Takarinda.
Visualization: Kudakwashe C. Takarinda, Andrew Phillips.
Writing – original draft: Tsitsi Apollo.
Writing – review & editing: Tsitsi Apollo, Kudakwashe C. Takarinda, Andrew Phillips, Chira-
tidzo Ndhlovu, Frances M. Cowan.
References
1. Joint United Nations Programme on HIV/AIDS (UNAIDS). Ending AIDS: Progress towards the 90-90-
90 targets. Geneva; 2017. Available: http://www.unaids.org/sites/default/files/media_asset/Global_
AIDS_update_2017_en.pdf
2. Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutierrez F, et al. Dolutegravir plus aba-
cavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013; 369: 1807–1818. https://doi.
org/10.1056/NEJMoa1215541 PMID: 24195548
3. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treat-
ing and preventing HIV infection: recommendations for a public health approach - 2nd ed. 2nd ed.
WHO. Geneva: WHO; 2016.
4. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral
Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375: 830–9. https://doi.org/10.
1056/NEJMoa1600693 PMID: 27424812
5. Ministry of Health and Child Care (MOHCC), National AIDS Council (NAC). GLOBAL AIDS
RESPONSE PROGRESS REPORT 2018 GAM ZIMBABWE COUNTRY REPORT Reporting Period:
January 2017—December 2017 Contents. Harare, Zimbabwe; 2018.
6. Medicines N, Policy Advisory Committee T, Aids T, Directorate T, of Health M, Care C. Guidelines for
Antiretroviral Therapy for the Prevention and Treatment of HIV in Zimbabwe National Medicines and
Therapeutics Policy Advisory Committee (NMTPAC) and The AIDS and TB Directorate, Ministry of
Health and Child Care, Zimbabwe. 2016.
7. Ministry of Health and Child Care (MOHCC). Zimbabwe Population-Based HIV Impact Assessment
(ZIMPHIA) 2015–16: First Report. Harare; 2017.
8. Child M of H and. Zimbabwe HIV Viral Load Scale-Up Plan 2015–2018 (no publication date). 2015.
9. Labhardt ND, Ringera I, Lejone TI, Cheleboi M, Wagner S, Muhairwe J, et al. When patients fail
UNAIDS’ last 90—The “failure cascade” beyond 90-90-90 in rural Lesotho, Southern Africa: A prospec-
tive cohort study: A. J Int AIDS Soc. 2017;20. https://doi.org/10.7448/IAS.20.1.21803 PMID: 28777506
10. MAKING VIRAL LOAD ROUTINE Successes and challenges in the implementation of routine HIV viral
load monitoring PART 1: PROGRAMMATIC STRATEGIES.
11. Hailu GG, Hagos DG, Hagos AK, Wasihun AG, Dejene TA. Virological and immunological failure of
HAART and associated risk factors among adults and adolescents in the Tigray region of Northern Ethi-
opia. PLoS One. 2018;13. https://doi.org/10.1371/journal.pone.0196259 PMID: 29715323
12. Ndagijimana Ntwali JDD, Decroo T, Ribakare M, Kiromera A, Mugwaneza P, Nsanzimana S, et al. Viral
load detection and management on first line ART in rural Rwanda. BMC Infect Dis. 2019;19. https://doi.
org/10.1186/s12879-018-3624-5 PMID: 30616531
13. Ehrenkranz PD, Baptiste SL, Bygrave H, Ellman T, Doi N, Grimsrud A, et al. The missed potential of
CD4 and viral load testing to improve clinical outcomes for people living with HIV in lower-resource set-
tings. PLoS Med. 2019;16. https://doi.org/10.1371/journal.pmed.1002820 PMID: 31141516
14. Lecher S, Williams J, Fonjungo PN, Kim AA, Ellenberger D, Zhang G, et al. Progress with Scale-Up of
HIV Viral Load Monitoring—Seven Sub-Saharan African Countries, January 2015-June 2016. MMWR
Morb Mortal Wkly Rep. 2016; 65: 1332–1335. https://doi.org/10.15585/mmwr.mm6547a2 PMID:
27906910
15. Pham MD, Romero L, Parnell B, Anderson DA, Crowe SM, Luchters S. Feasibility of antiretroviral treat-
ment monitoring in the era of decentralized HIV care: a systematic review. AIDS Res Ther. 2017; 14: 3.
https://doi.org/10.1186/s12981-017-0131-5 PMID: 28103895
16. Zimbabwe M of H and CC (MOHCC). OPERATIONAL AND SERVICE DELIVERY MANUAL. 2017.
PLOS ONE Viral load uptake in ART care in Zimbabwe
PLOS ONE | https://doi.org/10.1371/journal.pone.0245720 January 22, 2021 17 / 18
17. Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa,
Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, et al. Sustainable HIV treatment in Africa through
viral-load-informed differentiated care. Nature. 2015; 528: S68–76. https://doi.org/10.1038/
nature16046 PMID: 26633768
18. World Health Organization (WHO). THE AVAILABILITY AND USE OF HIV DIAGNOSTICS: A 2012/
2013 WHO SURVEY IN LOW-AND MIDDLE-INCOME COUNTRIES AIDS MEDICINES AND DIAG-
NOSTICS SERVICE. 2014.
19. Swannet S, Decroo T, de Castro SMTL, Rose C, Giuliani R, Molfino L, et al. Journey towards universal
viral load monitoring in Maputo, Mozambique: many gaps, but encouraging signs. Int Health. 2017; 9:
206–214. https://doi.org/10.1093/inthealth/ihx021 PMID: 28810670
20. Narainsamy D, Mahomed S. Delays in switching patients onto second-line antiretroviral treatment at a
public hospital in eThekwini, KwaZulu-Natal. South Afr J HIV Med. 2017;18. https://doi.org/10.4102/
sajhivmed.v18i1.696 PMID: 29568632
21. Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to second-
line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality out-
comes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017;17.
https://doi.org/10.1186/s12879-016-2105-y PMID: 28056820
22. Haas AD, Keiser O, Balestre E, Brown S, Bissagnene E, Chimbetete C, et al. Monitoring and switching
of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
lancet HIV. 2015; 2: e271–8. https://doi.org/10.1016/S2352-3018(15)00087-9 PMID: 26423252
23. Mwau M, Syeunda CA, Adhiambo M, Bwana P, Kithinji L, Mwende J, et al. Scale-up of Kenya’s national
HIV viral load program: Findings and lessons learned. PLoS One. 2018; 13: e0190659. https://doi.org/
10.1371/journal.pone.0190659 PMID: 29324811
24. Mutasa-Apollo T, Shiraishi RW, Takarinda KC, Dzangare J, Mugurungi O, Murungu J, et al. Patient
retention, clinical outcomes and attrition-associated factors of HIV-infected patients enrolled in Zim-
babwe’s National Antiretroviral Therapy Programme, 2007–2010. PLoS One. 2014; 9: e86305. https://
doi.org/10.1371/journal.pone.0086305 PMID: 24489714
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